Wedbush has assumed coverage of Voyager Therapeutics (NASDAQ:VYGR) with an outperform rating, highlighting the company’s ...

Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after ...

Key Takeaways Wedbush upgraded Snowflake as the analysts predicted that the artificial intelligence software era is ...

Wedbush would characterize demand for iPhone 16 so far since its September launch as “slightly ahead to generally in line with expectations ...

Wedbush notes that in the past two weeks Kioxia filed for an IPO and SanDisk released its 10-12B, telling investors that data from these ...

The EV maker’s stock gained 3.7% on Friday, leaving the shares ahead nearly 40% for the year and giving it a market value of ...

IMAX Corp.’s shares have climbed 71.2% in 2024, and analyst firm Wedbush sees more upside ahead for the high-end movie-theater operator.

Microsoft stock was lagging its tech peers on Friday as investors reacted to news the company is facing a broad inquiry from ...

Best Buy is one of the worst S&P 500 stocks Tuesday after the retailer missed quarterly earnings expectations and slashed its ...

Trump previously vowed to end federal electric vehicle tax credits, which are worth up to $7,500 for new zero-emission ...

Apple Inc.’s skeptics and bears have missed the last more than $1 trillion upward move in the stock by overlooking three key dynamics behind the story, Wedbush analysts said Friday. Apple has an ...

Tesla Inc. could see significant workforce changes if California Governor Gavin Newsom proceeds with excluding the company ...